Compare Citius Pharmaceuticals Inc (CTXR) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs T-Mobile Us Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while T-Mobile Us Inc trades at $188.15 (market cap $202.51B). The key difference: T-Mobile Us Inc is far larger — about 13832.7× Citius Pharmaceuticals Inc's market cap, and T-Mobile Us Inc pays a 2.18% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | TMUS | |
|---|---|---|
Market Cap | $14.64M | $202.51B |
Sector | Health | Media |
52-Week High | $1.82 | $259.01 |
52-Week Low | $0.53 | $167.65 |
Enterprise Value | $10.86M | $320.21B |
Dividend Yield | — | 2.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
T-Mobile US (TMUS) trades at $188.42, up 0.43% today, with a bullish technical signal and strong analyst support. The stock shows robust fundamentals with 2025 revenue of $88.31B and net income of $10.99B, though profit margins dipped slightly. Recent leadership changes and competitive threats from Starlink are in focus, while cash flow remains positive. The consensus price target is $243.09, implying significant upside.
Outlook remains positive given earnings beats and growth prospects, but risks include rising debt levels and satellite competition. Institutional sentiment is strongly bullish with 83% buy ratings, supporting a favorable risk-reward profile for long-term investors despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
